Objectives: Integrase strand-transfer inhibitor (InSTI)-based regimens are the preferred combinations for naïve HIV-infected individuals. Polymorphic substitutions that reduce InSTIs activity have been described, with E157Q being one of the most frequently found. This study aimed to evaluate the prevalence of E157Q substitution in newly diagnosed acute/recent HIV cases and the presence of transmission clusters.
Design: Prospective cohort study in patients with acute/recent HIV infection.
Methods: Genotypic drug resistance tests were performed in all consecutive patients prospectively enrolled with a documented infection of less than 6 months from May 2015 to May 2017. Sequences were obtained by ultra-deep sequencing. Phylogenetic inferences were performed using maximum likelihood trees constructed with Mega 6.06. Bootstrap values of 75% or greater were defined for cluster assignment. Follow-up was, at least, 1 year.
Results: In six out of 67 consecutive patients (8.95%, 95% confidence interval 4.17-18.19) with acute/recent HIV infection, strains carrying the E157Q InSTI substitution were detected. All cases were MSM patients infected with subtype B strains. No other resistance substitutions were detected in these cases. Median viral load was 5.33 (interquartile range: 4.54-5.71) log10 copies/ml and, in all cases, the mutational viral load was high (>95%). Three cases were included in transmission clusters. Three cases responded to dolutegravir-based regimens; nonnucleoside reverse transcriptase inhibitor-based regimens were used for the other case(s).
Conclusion: E157Q substitution, reducing raltegravir and elvitegravir activity, was frequently found in acute/recent HIV cases. All cases were infected with subtype B, and some were included in clusters. Cases treated with dolutegravir-based regimens had good virological response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0000000000002243 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: One size does not fit all.
Immun Inflamm Dis
March 2024
South African Medical Research Council, Cape Town, South Africa.
Passive immunoprophylaxis with broadly neutralizing monoclonal antibodies (bNAbs) could be a game changer in the prevention of human immunodeficiency virus (HIV) acquisition. The prevailing view is that available resources should be focused on identifying a fixed combination of at least three bNAbs for universal use in therapeutic and preventive protocols, regardless of target populations or routes of transmission. HIV transmission through breastfeeding is unique: it involves free viral particles and cell‐associated virus from breast milk and, in the case of acute/recent maternal infection, a viral population with restricted Env diversity.
View Article and Find Full Text PDFDemographics of Youth With Newly Diagnosed Acute/Recent HIV Infection in Adolescent Trials Network 147: Early Treatment of Acute HIV Infection.
J Adolesc Health
March 2024
Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Purpose: Gay, bisexual, and other cisgender men who have sex with men, and racial minority youth are at elevated risk of acquiring HIV infection. The Adolescent Trials Network 147 recruited youth with acute/recent HIV-infection for early antiretroviral treatment. The cohort make-up is described here.
View Article and Find Full Text PDFImpact of Latent M. tuberculosis Infection Treatment on Time to CD4/CD8 Recovery in Acute, Recent, and Chronic HIV Infection.
J Acquir Immune Defic Syndr
December 2023
Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil.
Introduction: In people living with HIV, active and latent tuberculosis (TB) coinfections are associated with immune activation that correlate with HIV progression and mortality. We investigated the effect of initiating antiretroviral therapy (ART) during acute (AHI), recent (RHI), or chronic HIV infection (CHI) on CD4/CD8 ratio normalization and associated factors, the impact of latent TB infection treatment, and prior/concomitant TB diagnosis at the time of ART initiation.
Methods: We included sex with men and transgender women individuals initiating ART with AHI, RHI and CHI between 2013 and 2019, from a prospective cohort in Brazil.
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
HIV Med
August 2022
Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Article Synopsis
- * Out of 1,325 participants, 28.6% tested positive for HCV antibodies, while only 2.2% had active HCV infections, showing a dramatic decline in rates from previous years due to increased treatment uptake.
- * Despite the heightened use of direct-acting antiviral agents leading to lower infection rates, a notable prevalence of HCV-related cirrhosis still existed, affecting 5.4% of the population studied.
Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection.
AIDS
December 2020
HIV Unit and Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona.
Objectives: Antiretroviral treatment (ART) during acute/recent HIV infection decreases transmission and optimizes immune recovery but the optimal ART-regimen in this setting is unknown. The objectives were to analyze the virological efficacy, immunological reconstitution and tolerability of different ART-regimens at 3 years after starting ART during acute/recent HIV infection.
Design: Retrospective cohort study of consecutive acutely/recently infected patients who started ART within 6 months postinfection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!